Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History
Open Access
- 24 November 2018
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (12) , 476
Abstract
Interstitial lung disease (ILD) and pulmonary fibrosis comprise a wide array of inflammatory and fibrotic lung diseases which are often confusing to general medicine and pulmonary physicians alike. In addition to the myriad of clinical and radiologic nomenclature used in ILD, histopathologic descriptors may be particularly confusing, and are often extrapolated to radiologic imaging patterns which may further add to the confusion. We propose that rather than focusing on precise histologic findings, focus should be on identifying an accurate etiology of ILD through a comprehensive and detailed medical history. Histopathologic patterns from lung biopsy should not be dismissed, but are often nonspecific, and overall treatment strategy and prognosis are likely to be determined more by the specific etiology of ILD rather than any particular histologic pattern. In this review, we outline a practical approach to common ILDs, highlight important aspects in obtaining an exposure history, clarify terminology and nomenclature, and discuss six common subgroups of ILD likely to be encountered by general medicine physicians in the inpatient or outpatient setting: Smoking-related, hypersensitivity pneumonitis, connective tissue disease-related, occupation-related, medication-induced, and idiopathic pulmonary fibrosis. Accurate diagnosis of these forms of ILD does require supplementing the medical history with results of the physical examination, autoimmune serologic testing, and chest radiographic imaging, but the importance of a comprehensive environmental, avocational, occupational, and medication-use history cannot be overstated and is likely the single most important factor responsible for achieving the best possible outcomes for patients.Keywords
Funding Information
- National Institutes of Health (R01HL126897)
- U.S. Department of Veterans Affairs (I01CX000101, I01BX002499)
This publication has 185 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Surfactant Protein A2 Mutations Associated with Pulmonary Fibrosis Lead to Protein Instability and Endoplasmic Reticulum StressJournal of Biological Chemistry, 2010
- My approach to interstitial lung disease using clinical, radiological and histopathological patternsJournal of Clinical Pathology, 2009
- Idiopathic Nonspecific Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Idiopathic Nonspecific Interstitial PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workersOccupational and Environmental Medicine, 2006